Company Description
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally.
The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers’ diarrhea in the United States, and Travelers’ Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection.
It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis.
Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
| Country | Australia |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Steven Lydeamore |
Contact Details
Address: 62 Lygon Street, Level 3 Carlton, VIC 3053 Australia | |
| Phone | 61 3 9824 5254 |
| Website | immuron.com.au |
Stock Details
| Ticker Symbol | IMRN |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| CIK Code | 0001660046 |
| CUSIP Number | 45254U101 |
| ISIN Number | US45254U1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven George Lydeamore CPA, M.B.A. | Chief Executive Officer |
| Dr. Jerry Kanellos Ph.D. | Chief Operating Officer |
| Flavio Palumbo | Chief Commercial Officer |
| Phillip Allen Hains BBus(Acc), C.A., M.B.A. | Chief Financial Officer and Company Secretary |
| David Lyon | Head of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2024 | 6-K | Report of foreign issuer |
| Oct 18, 2024 | 6-K | Report of foreign issuer |
| Oct 16, 2024 | 6-K | Report of foreign issuer |
| Oct 15, 2024 | 6-K | Report of foreign issuer |
| Oct 8, 2024 | 6-K | Report of foreign issuer |
| Oct 4, 2024 | 6-K | Report of foreign issuer |
| Oct 1, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Sep 26, 2024 | 6-K | Report of foreign issuer |
| Sep 9, 2024 | 6-K | Report of foreign issuer |
| Sep 5, 2024 | 6-K | Report of foreign issuer |